awmsg logo



adalimumab (Humira®)


Reference No. 1381

Publication date:
31/07/2013


Appraisal information

adalimumab (Humira®) 40 mg solution for injection


Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 15/05/2013
AWMSG meeting date: 12/06/2013
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 1513
Ministerial ratification: 29/07/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA383) NICE GUIDANCE ISSUED FEBRUARY 2016 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended for use within NHS Wales for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to non steroidal anti-inflammatory drugs (NSAIDs).
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download